Gianantonio Rosti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2543105/publications.pdf

Version: 2024-02-01

120	4,111	249298	134545
papers	citations	26 h-index	62 g-index

120	120	120	4478
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and safety of bosutinib in later-line patients (pts) with chronic myeloid leukemia (CML): A sub-analysis from the phase 4 BYOND trial.. Journal of Clinical Oncology, 2022, 40, e19055-e19055.	0.8	1
2	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 669-678.	0.6	10
3	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. Cancer Medicine, 2021, 10, 1726-1737.	1.3	9
4	Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. Frontiers in Oncology, 2021, 11, 638689.	1.3	0
5	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. Frontiers in Oncology, 2021, 11, 739171.	1.3	6
6	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia, 2020, 34, 488-498.	3.3	35
7	Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e144-e153.	0.2	0
8	Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies. Quality of Life Research, 2020, 29, 815-823.	1.5	12
9	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. Journal of Clinical Medicine, 2020, 9, 3692.	1.0	2
10	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia, 2020, 34, 2125-2137.	3.3	47
11	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia, 2020, 34, 2260-2261.	3.3	57
12	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood, 2020, 135, 534-541.	0.6	61
13	Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies. Value in Health, 2019, 22, 1303-1310.	0.1	18
14	Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia, 2019, 33, 2358-2364.	3.3	35
15	The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia, 2019, 33, 1173-1183.	3.3	83
16	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Advances, 2019, 3, 4280-4290.	2.5	66
17	Current treatment approaches in CML. HemaSphere, 2019, 3, 54-56.	1.2	2
18	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. Journal of Hematology and Oncology, 2019, 12, 131.	6.9	45

#	Article	IF	Citations
19	Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study. Blood, 2019, 134, 1639-1639.	0.6	5
20	Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study. Blood, 2019, 134, 1650-1650.	0.6	5
21	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. Blood, 2019, 134, 661-661.	0.6	5
22	Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors. Blood, 2019, 134, 496-496.	0.6	13
23	Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML).. Journal of Clinical Oncology, 2019, 37, 7012-7012.	0.8	4
24	Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia. Blood, 2019, 134, 4157-4157.	0.6	1
25	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. Blood, 2019, 134, 4153-4153.	0.6	0
26	Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study. Blood, 2019, 134, 2936-2936.	0.6	0
27	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. Blood, 2019, 134, 4142-4142.	0.6	0
28	Healthâ€related quality of life in patients with chronic myeloid leukemia receiving firstâ€line therapy with nilotinib. Cancer, 2018, 124, 2228-2237.	2.0	22
29	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Annals of Hematology, 2018, 97, 95-100.	0.8	32
30	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. Expert Opinion on Drug Safety, 2018, 17, 623-628.	1.0	10
31	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. Frontiers in Oncology, 2018, 8, 194.	1.3	84
32	Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. Oncotarget, 2018, 9, 21758-21769.	0.8	3
33	Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1225-1233.	1.2	9
34	The BCRâ€ABL1 transcript type influences response and outcome in <scp>P</scp>hiladelphia chromosomeâ€positive chronic myeloid leukemia patients treated frontline with imatinib. American Journal of Hematology, 2017, 92, 797-805.	2.0	71
35	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. Haematologica, 2017, 102, 1530-1536.	1.7	15
36	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1585-1596.	1.2	29

#	Article	IF	Citations
37	Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel. Critical Reviews in Oncology/Hematology, 2017, 120, 52-59.	2.0	38
38	Chronic myeloid leukemia: room for improvement?. Haematologica, 2017, 102, 1131-1133.	1.7	3
39	A populationâ€based study of chronic myeloid leukemia patients treated with imatinib in first line. American Journal of Hematology, 2017, 92, 82-87.	2.0	27
40	Physiciansâ€™ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients. Health and Quality of Life Outcomes, 2017, 15, 204.	1.0	0
41	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. Oncotarget, 2017, 8, 29906-29913.	0.8	22
42	Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget, 2017, 8, 49451-49469.	0.8	49
43	Rotation of nilotinib and imatinib for firstâ€line treatment of chronic phase chronic myeloid leukemia. American Journal of Hematology, 2016, 91, 617-622.	2.0	10
44	In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. BMC Cancer, 2016, 16, 572.	1.1	23
45	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 612-621.	5.1	214
46	Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Supportive Care in Cancer, 2016, 24, 4887-4894.	1.0	18
47	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. Haematologica, 2016, 101, 1200-1207.	1.7	22
48	Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. Tumor Biology, 2016, 37, 217-225.	0.8	2
49	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget, 2016, 7, 80083-80090.	0.8	24
50	Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. Oncotarget, 2016, 7, 21982-21990.	0.8	52
51	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica, 2015, 100, 1146-1150.	1.7	39
52	TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014005.	0.5	32
53	Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leukemia Research, 2014, 38, 294-298.	0.4	32
54	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell, 2014, 26, 428-442.	7.7	292

#	Article	IF	Citations
55	International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Quality of Life Research, 2014, 23, 825-836.	1.5	67
56	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122, 872-884.	0.6	1,743
57	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood, 2013, 121, 5138-5144.	0.6	49
58	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. Blood, 2013, 122, 258-258.	0.6	2
59	Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy. Blood, 2013, 122, 380-380.	0.6	2
60	The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. Blood, 2013, 122, 1486-1486.	0.6	0
61	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. Blood, 2013, 122, 4000-4000.	0.6	0
62	Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain. Blood, 2013, 122, 3986-3986.	0.6	0
63	Physicianâ€™s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. Cancer Treatment Reviews, 2012, 38, 241-248.	3.4	29
64	Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Critical Reviews in Oncology/Hematology, 2012, 82, 159-170.	2.0	20
65	Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications. Blood, 2012, 120, 692-692.	0.6	2
66	Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients. Blood, 2012, 120, 3733-3733.	0.6	0
67	A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission. Blood, 2011, 118, 2759-2759.	0.6	2
68	Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?. Blood, 2011, 118, 2770-2770.	0.6	1
69	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. Blood, 2011, 118, 453-453.	0.6	1
70	Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies. Blood, 2011, 118, 112-112.	0.6	6
71	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. Blood, 2011, 118, 786-786.	0.6	5
72	Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy. Blood, 2011, 118, 1026-1026.	0.6	0

#	Article	IF	Citations
73	Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. Blood, 2011, 118, 4445-4445.	0.6	0
74	APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. Blood, 2011, 118, 1686-1686.	0.6	0
75	Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,. Blood, 2011, 118, 3775-3775.	0.6	0
76	Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. Blood, 2011, 118, 2751-2751.	0.6	1
77	A Global Retrospective and Physician-Based Analysis of Adherence to Tyrosine Kinase Inhibitor (TKI) Therapies for Chronic Myeloid Leukemia (CML).. Blood, 2010, 116, 1514-1514.	0.6	7
78	Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd. Blood, 2010, 116, 2291-2291.	0.6	12
79	Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. Blood, 2010, 116, 2293-2293.	0.6	2
80	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. Blood, 2010, 116, 3413-3413.	0.6	2
81	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. Blood, 2010, 116, 359-359.	0.6	14
82	Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression. Blood, 2010, 116, 885-885.	0.6	5
83	Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.. Blood, 2010, 116, 1666-1666.	0.6	0
84	Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT.. Blood, 2010, 116, 1287-1287.	0.6	0
85	Risk Score at Diagnosis and the Dynamics of Response to TKI Therapy In Chronic Myeloid Leukemia.. Blood, 2010, 116, 1236-1236.	0.6	0
86	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. Blood, 2010, 116, 2281-2281.	0.6	0
87	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. Blood, 2010, 116, 1230-1230.	0.6	2
88	Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMolR) at 12 Months. Blood, 2010, 116, 668-668.	0.6	0
89	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. Blood, 2010, 116, 2273-2273.	0.6	0
90	Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood, 2009, 114, 4933-4938.	0.6	203

#	Article	IF	Citations
91	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.. Blood, 2009, 114, 2176-2176.	0.6	1
92	The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. Blood, 2009, 114, 2192-2192.	0.6	3
93	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. Blood, 2009, 114, 2205-2205.	0.6	8
94	Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience.. Blood, 2009, 114, 2027-2027.	0.6	0
95	The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.. Blood, 2009, 114, 4272-4272.	0.6	11
96	Outcome and Prognosis of 1955 Patients with Chronic Myeloid Leukemia: First Results of the CML-Registry of the European Treatment and Outcome Study EUTOS.. Blood, 2009, 114, 1109-1109.	0.6	0
97	CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.. Blood, 2009, 114, 2174-2174.	0.6	0
98	Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. Blood, 2008, 112, 185-185.	0.6	13
99	Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score. Blood, 2008, 112, 3190-3190.	0.6	4
100	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica, 2007, 92, 101-105.	1.7	57
101	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. Blood, 2007, 110, 26-26.	0.6	4
102	Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. Blood, 2006, 108, 836-836.	0.6	17
103	The European Leukemia Net CML Registry - Objectives, Achievements and First Results.. Blood, 2006, 108, 4781-4781.	0.6	0
104	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. Blood, 2006, 108, 4805-4805.	0.6	0
105	Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. Blood, 2005, 106, 1096-1096.	0.6	1
106	Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.. Blood, 2005, 106, 375-375.	0.6	3
107	Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML.. Blood, 2005, 106, 435-435.	0.6	4
108	Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. Blood, 2005, 106, 1100-1100.	0.6	0

#	Article	IF	Citations
109	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. Blood, 2005, 106, 1098-1098.	0.6	4
110	Comparison of Cytogenetics and Interphase Fluorescence In Situ Hybridization in Newly Diagnosed Ph+ Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. A Study by the GIMEMA Working Party on CML. On Behalf of GWP on CML.. Blood, 2005, 106, 4857-4857.	0.6	0
111	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood, 2004, 103, 2284-2290.	0.6	69
112	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement treated with Imatinib.. Blood, 2004, 104, 1507-1507.	0.6	1
113	A Novel 4-anilino-3-quinolinecarbonitrile Dual Src and Abl Kinase Inhibitor (SKI-606) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.. Blood, 2004, 104, 1991-1991.	0.6	5
114	A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.. Blood, 2004, 104, 4687-4687.	0.6	4
115	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.. Blood, 2004, 104, 4655-4655.	0.6	0
116	Imatinib in the Treatment of CML Patients â‰¥ 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. Blood, 2004, 104, 2935-2935.	0.6	0
117	Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.. Blood, 2004, 104, 4672-4672.	0.6	0
118	Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica, 2003, 88, 256-9.	1.7	20
119	Quantitative Evaluation of BCR-ABL Amount of Transcript Post Mobilization with G-CSF of Peripheral Blood Stem Cells from Chronic Myeloid Leukemia Patients in Cytogenetic Response. Leukemia and Lymphoma, 2000, 39, 113-120.	0.6	2
120	Highâ€dose therapy followed by autologous bone marrow transplantation (ABMT) in previously untreated nonâ€Hodgkin's lymphoma. European Journal of Haematology, 1986, 37, 347-352.	1.1	7